Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07174726 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

Study acronym: Landscape
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jun 30, 2027 to Dec 31, 2029
    • Trial status changed: Recruiting → Active, Not Recruiting
    • Study completion date: Dec 15, 2030 to Dec 30, 2030
    v8
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 6 of 6 sites
    v7
  3. Site details revised at 2 of 6 sitesv6
  4. Site details revised at 2 of 6 sitesv5
  5. Site details revised at 1 of 6 sitesv4
Show 2 earlier versionsHide 2 earlier versions
  1. Site details revised at 1 of 6 sitesv3
  2. Primary endpoint revised
    • Secondary endpoints revised (11)
    • Site contacts updated at 1 of 6 sites
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.
Trial Details
NCT Number NCT07174726
Lead Sponsor Beacon Therapeutics
Conditions
(from sponsor)		 X-Linked Retinitis Pigmentosa (XLRP)
Related terms Retinal Degeneration
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov